BiotechTube
i2o Therapeutics

i2o Therapeutics

Cambridge, United States· Est.
i2obio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $89M

Overview

i2o Therapeutics is a private, pre-clinical stage biotech focused on unlocking the potential of oral biologic drugs through its proprietary intestinal targeting delivery platform. The company's strategy centers on developing long-acting oral versions of key metabolic hormones, including GLP-1, amylin, PYY, and glucagon receptor agonists, with an eye toward combination therapies for obesity and related conditions. As a platform company, it is pre-revenue and likely backed by venture capital, positioning itself in one of the most competitive and high-value therapeutic areas in biopharma.

ObesityCardio-Renal-Metabolic Diseases

Technology Platform

Proprietary intestinal targeting platform for oral delivery of biologics and peptides, enabling long-acting formulations.

Funding History

3
Total raised:$89M
Series A$46M
Series A$35M
Seed$8M

Opportunities

The massive and rapidly expanding market for obesity and metabolic disease therapies presents a multi-billion dollar opportunity.
An effective oral combination therapy could achieve superior patient compliance and market penetration compared to injectables.
The platform technology, if validated, could be applied to other therapeutic areas beyond metabolism, creating significant partnership or licensing potential.

Risk Factors

High technical risk associated with achieving sufficient oral bioavailability and consistent delivery of biologic peptides.
Intense competition from large pharma and well-funded biotechs developing both injectable and oral next-generation metabolic therapies.
Dependency on future financing rounds in a potentially challenging capital environment for early-stage biotech.

Competitive Landscape

i2o operates in the highly competitive fields of oral peptide delivery and obesity therapeutics. It faces direct competition from companies like Novo Nordisk and Eli Lilly, who are advancing oral GLP-1s and multi-agonists, as well as from other biotechs focused on novel delivery technologies (e.g., Oramed, Entera Bio) and next-generation metabolic targets. Differentiation will require demonstrating clear advantages in efficacy, convenience, or combination synergy.

More companies in United States →